“We welcome Fundación de Investigación de Diego as our most recent client partner and look forward to seeing them reap the tremendous rewards that ALPHADAS will bring them” said Giles Wilson, BEng, CEO of Logos Technologies Inc. “Providing real-time reporting and review to their clients and Sponsors was an important requirement and through this partnership we look forward to life changing and life saving drugs reaching the market safely and more quickly.”

Mark Cusack, VP of Global Business Development at Logos Technologies commented “We have worked closely with Fundacion de Investigacion de Diego and their dedicated team to fully understand and support their goals. It is testament to the quality and innovation that is integral to ALPHADAS that it has been chosen by them as their system of choice. It means that ALPHADAS is now delivering unrivaled value in 4 continents – Europe, Asia, North America & South America. But to have a Key Opinion Leader such as Dr Maribel Rodriguez-Torres’ standing and experience excited and engaged with ALPHADAS and willing to participate in its future really is the ‘icing on the cake’. We are delighted.”

Fundación is recognized to be a center for excellence in medical care for patients with all types of liver diseases as well as a premier site for research for Latino patients. Their research expertise includes both clinical and pharmacokinetic, pharmacodynamic and pharmacogenetic assessments. They conduct phase I, II, III, IV studies, standard of care, induction and observational studies. Fundacion’s Founder & Medical Director, Dr. Maribel Rodriguez-Torres, states “The ALPHADAS System was the ideal choice for us.

It will enhance the considerable investment we have made in our new unit and will significantly drive clinical excellence, operational efficiency and enhanced client service. We are also excited about playing a dynamic and robust role in Logos Technologies’ ambitious development plans for ALPHADAS – Logos positively encourage a vigorous feedback loop so their clients are at the heart of their development plans, continually striving to exceed expectations. On top of that Logos were sensitive to our business needs and drivers, the stage of development we were at and recognized the investment we have made here and gone out of their way to support that. On every level, they made it an easy choice.”

Fundación evaluated several other products in the sector and initially sought out Logos Technologies because of a peer recommendation. ALPHADAS was chosen because of its depth of product functionality and the experience of Logos Technologies.

ALPHADAS, is an e-Source, pro-active EDC system designed specifically for early phase clinical trials which has achieved great success. It is a market proven solution that offers a depth of functionality other systems cannot. The dedicated team behind ALPHADAS are Experts in early Phase EDC and provide an unrivalled level of service, experience and expertise to its clients. Logos Technologies continues to invest in ALPHADAS, even further increasing its performance and functionality making it the system of choice for early phase EDC.